MX2023008016A - Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. - Google Patents
Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.Info
- Publication number
- MX2023008016A MX2023008016A MX2023008016A MX2023008016A MX2023008016A MX 2023008016 A MX2023008016 A MX 2023008016A MX 2023008016 A MX2023008016 A MX 2023008016A MX 2023008016 A MX2023008016 A MX 2023008016A MX 2023008016 A MX2023008016 A MX 2023008016A
- Authority
- MX
- Mexico
- Prior art keywords
- tasquinimod
- treatment
- pharmaceutically acceptable
- acceptable salt
- myelodysplastic syndrome
- Prior art date
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 title abstract 2
- 229950001899 tasquinimod Drugs 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Tasquinimod, o una sal farmacéutica aceptable del mismo, para su uso en el tratamiento del síndrome mielodisplásico (MDS).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21152018 | 2021-01-18 | ||
EP21201509 | 2021-10-07 | ||
EP21205665 | 2021-10-29 | ||
PCT/EP2022/050891 WO2022152902A1 (en) | 2021-01-18 | 2022-01-17 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023008016A true MX2023008016A (es) | 2023-07-13 |
Family
ID=80034981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023008016A MX2023008016A (es) | 2021-01-18 | 2022-01-17 | Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240091215A1 (es) |
EP (1) | EP4277628A1 (es) |
JP (1) | JP2024503372A (es) |
KR (1) | KR20230133317A (es) |
AU (1) | AU2022208424A1 (es) |
CA (1) | CA3204120A1 (es) |
IL (1) | IL304232A (es) |
MX (1) | MX2023008016A (es) |
WO (1) | WO2022152902A1 (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
BR112012033465A2 (pt) | 2010-07-09 | 2017-06-20 | Active Biotech Ab | método para preparar um composto |
EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
KR102533033B1 (ko) | 2014-09-23 | 2023-05-15 | 액티브 바이오테크 에이비 | 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드 |
US10300053B2 (en) | 2014-11-19 | 2019-05-28 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of leukemia |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
-
2022
- 2022-01-17 EP EP22700096.5A patent/EP4277628A1/en active Pending
- 2022-01-17 CA CA3204120A patent/CA3204120A1/en active Pending
- 2022-01-17 MX MX2023008016A patent/MX2023008016A/es unknown
- 2022-01-17 KR KR1020237026973A patent/KR20230133317A/ko unknown
- 2022-01-17 WO PCT/EP2022/050891 patent/WO2022152902A1/en active Application Filing
- 2022-01-17 JP JP2023541564A patent/JP2024503372A/ja active Pending
- 2022-01-17 US US18/272,326 patent/US20240091215A1/en active Pending
- 2022-01-17 AU AU2022208424A patent/AU2022208424A1/en active Pending
-
2023
- 2023-07-04 IL IL304232A patent/IL304232A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3204120A1 (en) | 2022-07-21 |
JP2024503372A (ja) | 2024-01-25 |
KR20230133317A (ko) | 2023-09-19 |
US20240091215A1 (en) | 2024-03-21 |
WO2022152902A1 (en) | 2022-07-21 |
AU2022208424A9 (en) | 2024-05-09 |
AU2022208424A1 (en) | 2023-08-24 |
EP4277628A1 (en) | 2023-11-22 |
IL304232A (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001957A (es) | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). | |
NZ763551A (en) | Compounds useful for inhibiting cdk7 | |
MY190855A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
CA3018932C (en) | Pharmaceutical combinations for the treatment of cancer | |
EA202090061A1 (ru) | Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза | |
PH12019502197A1 (en) | Macrocyclic compound and uses thereof | |
MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
MX2021002321A (es) | Nuevos metodos. | |
TN2019000211A1 (en) | Antitumoral compounds | |
MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
MX2022007626A (es) | Combinaciones. | |
MX2015014958A (es) | Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma. | |
MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
CA3011003A1 (en) | Bacterial ghosts for the treatment of cancer | |
MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
IL288864A (en) | Treatment that includes sglt inhibitors, for example sglt 1/2 inhibitors | |
NZ733451A (en) | Combination therapy for pulmonary hypertension | |
PH12021551138A1 (en) | Application of chidamide in combination with r-chop, and drug combination | |
MX2022001647A (es) | Terapia de combinacion con vildagliptina y metformina. | |
MX2023008016A (es) | Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. | |
EA202091169A1 (ru) | Применяемые в качестве ингибиторов iap миметики smac и их применение | |
MX2020003427A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
MX2020008504A (es) | Agentes terapeuticos para tratar el sindrome de piernas inquietas. | |
MX2022007625A (es) | Combinaciones. | |
MX2022007623A (es) | Combinaciones. |